CA2436850A1 - Protease inhibitors - Google Patents

Protease inhibitors Download PDF

Info

Publication number
CA2436850A1
CA2436850A1 CA002436850A CA2436850A CA2436850A1 CA 2436850 A1 CA2436850 A1 CA 2436850A1 CA 002436850 A CA002436850 A CA 002436850A CA 2436850 A CA2436850 A CA 2436850A CA 2436850 A1 CA2436850 A1 CA 2436850A1
Authority
CA
Canada
Prior art keywords
6alkyl
substituted
group
methyl
benzofuran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002436850A
Other languages
English (en)
French (fr)
Inventor
Daniel F. Veber
Robert W. Marquis, Jr.
Dennis S. Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2436850A1 publication Critical patent/CA2436850A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002436850A 2000-11-22 2001-11-19 Protease inhibitors Abandoned CA2436850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25250800P 2000-11-22 2000-11-22
US60/252,508 2000-11-22
PCT/US2001/051647 WO2003053331A2 (en) 2000-11-22 2001-11-19 Protease inhibitors

Publications (1)

Publication Number Publication Date
CA2436850A1 true CA2436850A1 (en) 2003-07-03

Family

ID=22956303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002436850A Abandoned CA2436850A1 (en) 2000-11-22 2001-11-19 Protease inhibitors

Country Status (17)

Country Link
EP (1) EP1392657A4 (zh)
JP (1) JP2005513083A (zh)
KR (1) KR20040004445A (zh)
CN (1) CN1635903A (zh)
AR (1) AR034278A1 (zh)
AU (1) AU2001298052A1 (zh)
BR (1) BR0115473A (zh)
CA (1) CA2436850A1 (zh)
CZ (1) CZ20031403A3 (zh)
HU (1) HUP0301964A3 (zh)
IL (1) IL155997A0 (zh)
MX (1) MXPA03004542A (zh)
NO (1) NO20032328L (zh)
PL (1) PL366232A1 (zh)
UY (1) UY27032A1 (zh)
WO (1) WO2003053331A2 (zh)
ZA (1) ZA200303848B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
CN1416346A (zh) 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
AU2001268407A1 (en) * 2000-06-14 2001-12-24 Smithkline Beecham Corporation Protease inhibitors
CN101970007A (zh) 2007-06-08 2011-02-09 日本化学医药株式会社 脑动脉瘤的治疗或预防药
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511710A (en) * 1998-12-23 2003-12-19 Smithkline Beecham Corp 4-Amino-azepan-3-one derivatives useful as protease inhibitors
CN1416346A (zh) * 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
AU2001268407A1 (en) * 2000-06-14 2001-12-24 Smithkline Beecham Corporation Protease inhibitors

Also Published As

Publication number Publication date
CZ20031403A3 (cs) 2003-10-15
UY27032A1 (es) 2002-07-31
WO2003053331A3 (en) 2003-11-13
MXPA03004542A (es) 2003-09-10
JP2005513083A (ja) 2005-05-12
PL366232A1 (en) 2005-01-24
EP1392657A2 (en) 2004-03-03
WO2003053331A2 (en) 2003-07-03
HUP0301964A2 (en) 2007-02-28
CN1635903A (zh) 2005-07-06
EP1392657A4 (en) 2004-03-10
NO20032328L (no) 2003-07-02
KR20040004445A (ko) 2004-01-13
AU2001298052A1 (en) 2003-07-09
IL155997A0 (en) 2003-12-23
NO20032328D0 (no) 2003-05-22
BR0115473A (pt) 2004-09-28
ZA200303848B (en) 2004-06-28
AR034278A1 (es) 2004-02-18
HUP0301964A3 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
AU2001243441B2 (en) Protease inhibitors
AU2001243441A1 (en) Protease inhibitors
US20030225061A1 (en) Protease inhibitors
EP1320370A1 (en) Method of treatment
US7405209B2 (en) Protease inhibitors
CA2412353A1 (en) Protease inhibitors
CA2436850A1 (en) Protease inhibitors
WO2001089451A2 (en) Protease inhibitors
US20050256100A1 (en) Protease inhibitors
US20040038965A1 (en) Protease inhibitors
EP1384713B1 (en) 4-amino-azepan-3-one derivatives as protease inhibitors
AU2003261482B2 (en) Protease inhibitors
EP1534292A2 (en) Protease inhibitors
WO2003104257A2 (en) Protease inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued